Related Experiment Video
Updated: May 31, 2025

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module
Published on: June 18, 2015
Soy Isoflavone Genistein Enhances Tamoxifen Sensitivity in Breast Cancer via microRNA and Glucose Metabolism
Jessica Shpigel1, Emilia F Luciano1, Blessing Ukandu1
1Department of Chemistry, Herbert H. Lehman College, City University of New York, New York, NY 10468, USA.
Abstract:
Breast cancer treatment has advanced significantly, particularly for estrogen receptor-positive (ER+) tumors. Tamoxifen, an estrogen antagonist, is widely used; however, approximately 40% of patients develop resistance. Recent studies indicate that microRNAs, especially miR-155, play a critical role in this resistance. Our analysis of MCF-7 tamoxifen-sensitive (TAM-S) and tamoxifen-resistant (TAM-R) cells revealed that miR-155 is significantly upregulated in TAM-R cells. Overexpression of miR-155 in TAM-S cells increased resistance to tamoxifen. Additionally, genistein, a natural isoflavone from soybeans, effectively downregulated miR-155 and its targets associated with apoptosis and glucose metabolism, including STAT3 and hexokinase 2 (HK2). Notably, genistein also significantly decreased cell migration, suggesting potential anti-metastatic effects. Furthermore, genistein reduced glucose consumption, indicating its potential to overcome miR-155-mediated tamoxifen resistance and modulate the Warburg effect. These findings highlight genistein as a promising therapeutic agent for overcoming tamoxifen resistance in ER+ breast cancer and merit further investigation.
Insights
Genistein, a soy isoflavone, combats tamoxifen resistance in estrogen receptor-positive breast cancer by downregulating miR-155. This natural compound also shows potential anti-metastatic and anti-Warburg effect properties.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Estrogen receptor-positive (ER+) breast cancer treatment often involves tamoxifen, an estrogen antagonist.
- Tamoxifen resistance develops in about 40% of patients, necessitating alternative therapeutic strategies.
- MicroRNAs, particularly miR-155, have emerged as key regulators in tamoxifen resistance.
Purpose of the Study:
- To investigate the role of miR-155 in tamoxifen resistance in ER+ breast cancer cells.
- To evaluate the efficacy of genistein, a soy isoflavone, in overcoming tamoxifen resistance.
- To explore genistein's effects on miR-155 expression, related molecular targets, and cancer cell behavior.
Main Methods:
- Comparative analysis of miR-155 expression in tamoxifen-sensitive (TAM-S) and tamoxifen-resistant (TAM-R) MCF-7 breast cancer cells.
- Overexpression of miR-155 in TAM-S cells to assess its impact on tamoxifen sensitivity.
- Treatment of cells with genistein to evaluate its effects on miR-155, STAT3, hexokinase 2 (HK2), cell migration, and glucose metabolism.
Main Results:
- miR-155 was significantly upregulated in TAM-R cells compared to TAM-S cells.
- Overexpressing miR-155 in TAM-S cells conferred tamoxifen resistance.
- Genistein downregulated miR-155 and its targets (STAT3, HK2), reduced cell migration, and decreased glucose consumption, suggesting modulation of the Warburg effect.
Conclusions:
- miR-155 is a critical factor in tamoxifen resistance in ER+ breast cancer.
- Genistein demonstrates potential as a therapeutic agent to overcome tamoxifen resistance.
- Genistein may possess anti-metastatic properties and can modulate glucose metabolism in breast cancer cells.
Related Concept Videos
Oral Hypoglycemic Agents: Biguanides and Glitazones
MicroRNAs
Cancer Prevention
Some...
Internal Receptors

